Limits...
Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.

Ford JA, Shyangdan D, Uthman OA, Lois N, Waugh N - BMJ Open (2014)

Bottom Line: We found no evidence of differences between ranibizumab, aflibercept, bevacizumab and triamcinolone for improving vision.The antivascular endothelial growth factors (VEGFs) are likely to be favoured because they are not associated with steroid-induced cataract formation.Not registered.

View Article: PubMed Central - PubMed

Affiliation: Department of Population Health and Primary Care, University of East Anglia, Norwich, UK.

No MeSH data available.


Related in: MedlinePlus

Study selection flow diagram.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4120318&req=5

BMJOPEN2014005292F1: Study selection flow diagram.

Mentions: The literature search identified 945 articles, as shown in figure 1. Seven studies were judged to be sufficiently comparable to be included in the NMA. Tables 1 and 2 present the characteristics and results of the included trials. Two studies11–13 compared aflibercept 2 mg against sham; two identical studies6–8 compared dexamethasone 0.7 mg (Ozurdex) against sham; one study910 compared ranibizumab 0.5 mg against sham; one study42–44 compared bevacizumab 1.25 mg against sham and, finally, one study23–36 compared triamcinolone 4 mg against observation. Sham or observation was used as the common comparator. The number of included participants varied from 6042–44 to 437.6–8 Most studies required patients to be treatment naïve and have macular oedema with retinal thickness measuring at least 250 or 300 μm on optical coherence tomography. Sham injection was undertaken by placing a needleless syringe on the eye. All studies, except for Epstein et al,42–44 were multi-centre, international studies. Most studies had an extension phase after the primary outcome, but this was not included in the NMA.


Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.

Ford JA, Shyangdan D, Uthman OA, Lois N, Waugh N - BMJ Open (2014)

Study selection flow diagram.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4120318&req=5

BMJOPEN2014005292F1: Study selection flow diagram.
Mentions: The literature search identified 945 articles, as shown in figure 1. Seven studies were judged to be sufficiently comparable to be included in the NMA. Tables 1 and 2 present the characteristics and results of the included trials. Two studies11–13 compared aflibercept 2 mg against sham; two identical studies6–8 compared dexamethasone 0.7 mg (Ozurdex) against sham; one study910 compared ranibizumab 0.5 mg against sham; one study42–44 compared bevacizumab 1.25 mg against sham and, finally, one study23–36 compared triamcinolone 4 mg against observation. Sham or observation was used as the common comparator. The number of included participants varied from 6042–44 to 437.6–8 Most studies required patients to be treatment naïve and have macular oedema with retinal thickness measuring at least 250 or 300 μm on optical coherence tomography. Sham injection was undertaken by placing a needleless syringe on the eye. All studies, except for Epstein et al,42–44 were multi-centre, international studies. Most studies had an extension phase after the primary outcome, but this was not included in the NMA.

Bottom Line: We found no evidence of differences between ranibizumab, aflibercept, bevacizumab and triamcinolone for improving vision.The antivascular endothelial growth factors (VEGFs) are likely to be favoured because they are not associated with steroid-induced cataract formation.Not registered.

View Article: PubMed Central - PubMed

Affiliation: Department of Population Health and Primary Care, University of East Anglia, Norwich, UK.

No MeSH data available.


Related in: MedlinePlus